ZVRA · Zevra Therapeutics

The thesis

Zevra Therapeutics is modestly more likely to beat the S&P 500 over the next three months than to lag it. MIPLYFFA (arimoclomol, its drug for Niemann-Pick disease type C, a rare inherited disorder) reached $34.0 million of net revenue in the third quarter of 2026, and the company earned $19.2 million. The re-examination of arimoclomol by the European Medicines Agency (EMA) settles the European half of the case; the company had guided to a fourth-quarter 2026 outcome.

The shares closed at $11.16 on 12 November 2026, down from $12.14 on 9 November 2026 and $11.59 on 6 November 2026. The three-month price change is –1.4%, measured from the $11.32 close of 14 August 2026. The report of 3 November 2026 produced a recovery from the $10.53 close of 5 November 2026, and part of that move has since reversed.

Bullish and bearish views on Zevra Therapeutics, Inc.

The bull case on Zevra Therapeutics, Inc. (ZVRA), in brief: US drug sales are the core of revenue. The bear case: europe is an efficacy dispute.

Bull case

• US drug sales are the core of revenue. Zevra reported MIPLYFFA net revenue of $34.0 million for the third quarter of 2026 on 3 November 2026. Total net revenue was $37.8 million, up 45% from $26.1 million a year earlier.
• Results beat estimates. Benzinga-reported consensus figures put third-quarter sales at $37.079 million and adjusted earnings at $0.16 per share. The company posted $37.756 million and $0.176 on 3 November 2026.
• The company is profitable with a large cash balance. Cash, equivalents and investments were $270.9 million on 30 September 2026. Third-quarter net income was $19.2 million, including a $5.1 million non-cash gain on warrant and contingent value right liabilities.
• A second US growth path is planned. After an FDA meeting, Zevra expects to file a supplemental application for infants under 24 months in the first quarter of 2027, per the third-quarter release.
• Insiders sold only under pre-set plans. SEC Form 4 filings show the chief executive sold 20,000 shares at $11.25 on 12 October 2026 after exercising 50,000 options, and the chief legal officer sold 42,666 shares at $11.13 on 14 August 2026. Both used Rule 10b5-1 plans, which fix sales in advance.

Bear case

• Europe is an efficacy dispute. The EMA said on 24 July 2026 that efficacy was not sufficiently demonstrated. The third-quarter release says Zevra is awaiting the outcome and gives no timeline.
• New US patient additions are small. Zevra received 13 US prescription enrollment forms in the third quarter, for 197 since launch. The patient pool is finite, and growth beyond it depends on the infant label.
• One product carries the company. MIPLYFFA was $34.0 million of $37.8 million in third-quarter net revenue, so a US stall would hit nearly the whole revenue base.
• Spending is rising. Selling, general and administrative expense was $19.1 million against $16.9 million a year earlier, and research and development was $4.9 million against $3.4 million. Zevra gave no numerical revenue guidance.
• Expanded-access revenue is not product sales. Global Expanded Access Program reimbursements were $3.6 million in the third quarter, from 134 patients enrolled at 30 September 2026. That revenue ends for a patient once commercial supply reaches them.
• The celiprolol trial has no date. The DiSCOVER trial had 72 patients enrolled and 4 confirmed events at 30 September 2026. Its interim analysis is triggered by 28 events, so timing follows event accrual.

Price setup

The last close of $11.16 on 12 November 2026 sits just above the 50-day average of $11.06 and the 200-day average of $10.85. The shares closed at $12.14 on 9 November 2026 and fell to $11.85 on 11 November 2026 and $11.16 on 12 November 2026.

The 52-week intraday high is $15.04, reached on 8 July 2026, and the last close is 25.8% below it. The 52-week closing low is $8.10, set on 18 December 2025. Holding above both moving averages keeps the post-report recovery intact; a close under them would mean the report's effect has faded.

Catalysts ahead

• ~31 December 2026 (est.): EMA re-examination outcome on arimoclomol; Zevra earlier guided to the fourth quarter of 2026 and gave no date in the third-quarter release. A reversal of the 24 July 2026 negative opinion would reopen the European market; a repeat would close that path.
• ~31 March 2027 (est.): Planned supplemental application for MIPLYFFA in infants under 24 months, expected in the first quarter of 2027. Filing would widen the US label and the treatable patient pool.

What would change the view

A daily close below $9.80, which would erase the recovery that followed the third-quarter report. MIPLYFFA net revenue at or below $34.0 million in the fourth quarter of 2026, or a repeat negative opinion from the European Medicines Agency, would also break the case.

The risks this note tracks, each with what would confirm it:

• US MIPLYFFA growth stalls in a small patient pool as new enrollments hold near 13 a quarter. Confirmed by: fourth-quarter 2026 MIPLYFFA net revenue at or below the $34.0 million of the third quarter, or enrollment forms well under 13.
• European arimoclomol approval remains blocked after re-examination. Confirmed by: the EMA's final opinion repeating the 24 July 2026 efficacy conclusion.
• Fading expanded-access reimbursement and rising spending erode earnings. Confirmed by: Expanded-access revenue below the $3.6 million of the third quarter together with selling, general and administrative expense above $19.1 million.

What it trades with

Zevra trades on its own rare-disease sales and regulatory events more than on sector moves. The EMA decision is a binary event for the European market. Small-cap biotech funding sentiment affects the shares, but no peer data supports a measured link here. Analyst targets dated before the 3 November 2026 report are not cited.